Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia.

Trial Profile

Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 May 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Planned number of patients changed from 17 to 9 as reported by ClinicalTrials.gov.
    • 01 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top